

CURRICULUM VITAE

Peter Farvolden, PhD, CPsych

BUSINESS ADDRESS: 1332 County Road 3
Carrying Place, Ontario
K0K 1L0
p: 416-428 9030
e: drfarvolden@gmail.com

EDUCATION

1998 Ph.D. Clinical Psychology (Waterloo)
1991 B.Sc. Psychology (Waterloo)
1987 B.A. Philosophy (Waterloo)

LICENSURE

Registered Psychologist, The College of Psychologists of Ontario (CPO #3508)

EMPLOYMENT

Academic Appointments

2001 – 2016 Assistant Professor, Department of Psychiatry, University of Toronto
2003 – 2017 Assistant Adjunct Professor, Department of Psychology, University of Waterloo
2006 – 2019 Adjunct Professor, Department of Psychology, Toronto Metropolitan University

Professional and Administrative Employment

1998 – present Psychologist in private practice
2023 – present Mental Health Consultant, Global Team, Reinsurance Group of America
2016 – 2021 Founder, Chief Science Officer, Mindbeacon Health
2003 – 2016 Founder, Senior Clinical Director, CBT Associates
2006 – 2009 Clinical Director, Work, Stress and Health Program, Centre for Addiction and Mental Health
2005 – 2009 Clinical Director, Psychological Trauma Program, Centre for Addiction and Mental Health
2001 - 2005 Research Scientist, Clinical Research Department, Section on Personality and Psychopathology, Centre for Addiction and Mental Health
1998 - 2001 Psychologist, Anxiety Disorders Clinic, McMaster University Medical Centre
1997 - 1998 Psychology Intern, The Toronto Hospital

SELECTED RESEARCH ACTIVITIES

Grants/Contracts

- 2008- 2011 Development of a Best Practice Intervention for PTSD in the TTC. Grant Awarded by the Workplace Safety and Insurance Board Research Advisory Council, \$146,000.00.
- 2005 - 2006 Spectrum of Depressive Disorders and Pathological Gambling (Co-Investigator). Grant awarded by Ontario Problem Gambling Research Centre, \$524,417.32.
- 2005 - 2006 The Heterogeneity of Problem Gambling: An Analysis of Gambling Sub-Types (Co-Investigator). Grant awarded by Ontario Problem Gambling Research Centre, \$210,000.
- 2004 - 2005 Pharmacotherapy-Assisted Extinction (Pharmacoeextinction): A Novel Approach to the Treatment of Nicotine Dependence in Humans (Co-Applicant). Canadian Tobacco Control Research Initiative, \$50,000.00
- 2002 - 2006 Behavioural Inhibition, Behavioural Activation, Personality, and Novelty (Principal Investigator). Social Sciences and Humanities Research Council of Canada, \$102,921.
- 2002 - 2003 Personality and Cognitive Functioning in Problem Gambling (Co-Investigator). Funded by The Ontario Problem Gambling Foundation, \$ 196,000.00
- 2002 - 2003 Childhood Adversity, Adult Attachment Style, and Interpersonal Functioning in Depression" (Principal Investigator). Funded by a Research in Psychiatry Grant at The Centre for Addiction and Mental Health, \$ 5,313.03.
- 1998 - 2003 Industry-sponsored grants and contracts from Eli Lilly, Glaxo Smith Kline, Pfizer, Bristol Myers Squibb, and Jansen-Ortho.
- 1992 - 1995 PhD Dissertation research funded by a National Science and Engineering Research Council (NSERC) fellowship.

SELECTED PUBLICATIONS

Journal Articles

Chopra, K., Ravindran, A., **Farvolden, P.**, Bagby, R.M., Kennedy, S.H., MacKenzie, B., Matthews, S. PhD, & Levitan, R.D. (2010). Neuroticism Mediates Cortisol Stress Responses to the Trier Social Stress Test in Chronic Depression. *American Journal of Psychiatry*, 34 (8), 1235 -41.

Farvolden, P., Selby, P. & Cunningham, J. (2009). Using eHealth programs to overcome barriers to the effective treatment of mental health and addiction problems. *Journal of Technology in Human Services*, 28(1),

Bender, A., & **Farvolden, P.** (2008). Depression in the workplace: A progress report. *Current Psychiatry Reports*, 10(1), 73-79.

Quilty, L.C., Oakman, J.M., & **Farvolden, P.** (2007). Behavioural inhibition, behavioural activation, and preference for familiarity. *Journal of Personality*, 42(2), 291-303.

Sloman, L., **Farvolden, P.**, Gilbert, P., & Price, J. (2006). The interactive functioning of anxiety and depression in agonistic encounters and reconciliation. *Journal of Affective Disorders*, 90, 93-99.

Eastwood, J.D., Oakman, J.M., **Farvolden, P.**, Van Ameringen, M., Mancini, C., & Merikle, P.M. (2005). Individuals with social phobia are biased to become aware of negative faces. *Visual Cognition*, 12, 159-179.

Farvolden, P., Denisoff, E., Selby, P., Bagby, R.M., & Rudy, L. (2005). Usage and Longitudinal effectiveness of a freely available web-based self-help CBT program for panic disorder. *Journal of Medical Internet Research*, 26;7(1):e7.

Cohen, N.L., Hewitt, E.C., Bagby, R.M., **Farvolden, P.**, & Kennedy, S.H. (2004). Personality characteristics as predictors of antidepressant drug adherence. *Canadian Journal of Psychiatry*, 49, 106-113.

Farvolden, P. & Woody, E.Z. (2004). Hypnosis and memory: Effort, dissociation, and frontal lobe functioning. *International Journal of Clinical and Experimental Hypnosis*, 52, 3-26.

Van Ameringen, M., Mancini, C., Szechtman, H., Nahmias, C., Oakman, J.M., Hall, G.B., Pipe, B., **Farvolden, P.** (2004) A PET provocation study of generalized social phobia. *Psychiatry Research*, 15, 132(1):13-18.

Farvolden, P., Kennedy, S.H., & Lam, R. (2003). Recent developments in the psychobiology and pharmacotherapy of depression: Optimizing existing treatments and novel approaches for the future. *Expert Opinion on Investigational Drugs*, 12, 65-86.

Farvolden, P., McBride, C., Bagby, R.M., & Ravitz, P. (2003). A web-based screening instrument for depression and anxiety disorders in primary care. *Journal of Medical Internet Research*, <http://www.jmir.org/2003/3/e23/>

Oakman, J.M., Gifford, S., Van Ameringen, M., Mancini, C., & **Farvolden, P.**(2003). A confirmatory factor analysis of a self-report version of the Liebowitz Social Anxiety Scale. *Journal of Clinical Psychology*, 59, 149-161.

Quilty, L., Van Ameringen, M., Mancini, C., Oakman, J.M., & **Farvolden, P.** (2003). Quality of life and the anxiety disorders. *Journal of Anxiety Disorders*, 17, 405-426.

There is actually a separate Quilty et al article on educational achievement.

Reid, G.J., Chan, A.D.F., **Farvolden, P.**, Dean, M.L., & Bisailon, S. (2003). Learning needs of patients with congestive heart failure. *The Canadian Journal of Cardiology*, 19, 413-417.

Mancini, C., Van Ameringen, M., & **Farvolden, P.** (2002). Does SSRI augmentation with antidepressants that influence noradrenergic function resolve depression in obsessive compulsive disorder? *Journal of Affective Disorders*, 68, 59-65.

Van Ameringen, M., Mancini, C., **Farvolden, P.**, & Oakman, J.M. (2002). The impact of anxiety disorders on school functioning and educational underachievement. *Journal of Anxiety Disorders*, 433, 1-11.

Mancini, C., Van Ameringen, M., **Farvolden, P.** & Oakman J.M. (2001). Understanding and managing treatment resistant depression in anxiety disorders. *Essential Psychopharmacology*, 4, 23-26.

Mancini, C., Van Ameringen, M., **Farvolden, P.** & Oakman J.M. (2001). Understanding and managing treatment resistant depression in anxiety disorders. *Directions in Psychiatry*, 21, 175-185.

Van Ameringen, M., Mancini, C., **Farvolden, P.**, & Oakman, J.M. (2000). Drugs in development for social phobia: More to social phobia than meets the SSRI. *Expert Opinion on Investigational Drugs*, 9, 2215-2231.

Van Ameringen, M., Mancini, C., **Farvolden, P.** & Oakman, J.M. (2000). The neurobiology of social phobia: From pharmacotherapy to brain imaging. *Current Psychiatry Reports*, 2, 358-366.

Van Ameringen, M., Mancini, C., Oakman, J.M., & **Farvolden, P.** (2000). The potential role of haloperidol in the treatment of trichotillomania. *Journal of Affective Disorders*, 56, 219-226.

Mancini, C., Van Ameringen, M., Oakman, J.M., & **Farvolden, P.** (1999). Serotonergic agents in the treatment of social phobia in children and adolescents: A case series. *Depression and Anxiety*, 10, 33-39.

Van Ameringen, M., Mancini, C., **Farvolden, P.**, & Oakman, J.M. (1999). Pharmacotherapy of social phobia: What works, what might work and what doesn't work at all. *CNS Spectrums*, 4, 61-68.

Van Ameringen, M., Mancini, C., Oakman, J.M., & **Farvolden, P.** (1999). Selective serotonin reuptake inhibitors in the treatment of social phobia: The emerging gold standard. *CNS Drugs*, 11, 307-315.

Woody, E.Z. & **Farvolden, P.** (1998). Dissociation in hypnosis and frontal executive functioning. *American Journal of Clinical Hypnosis*, 40, 206-216.

Bowers, K.S. & **Farvolden, P.** (1996). The search for the canonical experience: Reply to Pennebaker and Memon. *Psychological Bulletin*, 116, 386-389.

Bowers, K.S. & **Farvolden, P.** (1996). Revisiting a century-old Freudian slip--from suggestion disavowed to the Truth repressed. *Psychological Bulletin*, 116, 355-380.

Journal Articles Accepted for Publication

Landy, M.S.H., Newman, L., Carney, A.E., Donkin, V., Nicholls, J. Krol, S.J., & **Farvolden, P.** (in press) Therapist-Assisted Internet-Delivered Cognitive Behavioral Therapy for Insomnia: A Case Report., *Clinical Case Studies*.

Chapters in Books

McBride, C., **Farvolden, P.**, & Swallow, S. (2007). Major depressive disorder. In (Eds.), P. du Toit, L.P. Riso, D.J. Stein, & J.E. Young. *Cognitive Schemas and Core Beliefs in Psychological Problems: A Scientist-Practitioner Guide* (pp.11-40). APA Books.

Kennedy, S.H., **Farvolden, P.**, Cohen, N.L., Bagby, R.M., & Costa, P. T. Jr. (2005). Personality and the pharmacological treatment of depression. In (Eds.), M. Rosenbluth, S. Kennedy, & R.M. Bagby. *Personality Dimensions, Disorders & Depression: Models & Implications for Treatment*. Arlington, VA: APA.

Bagby, R.M. & **Farvolden, P.** (2003). The Personality Diagnostic Inventory 4+ (PDI 4+). In (Eds.), M. Hersen, D.L. Segal, & M.J. Hilsenroth, *The Comprehensive Handbook of Personality Assessment, Volume 2: Personality Assessment* (pp. 122-133). New York, NY: Wiley.

Van Ameringen, M., Oakman, J.M., Mancini, C., & **Farvolden, P.** (2001). Obsessive-compulsive spectrum disorders: From serotonin to dopamine and back again. In (Eds.), N.A. Fineberg, D. Marazitti, & D. Stein, *Obsessive-Compulsive Disorders: A Practical Guide to Management* (pp. 23-36). New York: Martin Dunitz.

Oakman, J.M., **Farvolden, P.**, Van Ameringen, M., & Mancini, C. (2000). Challenges in the treatment of shyness and social phobia. In (Ed.), W.R. Crozier, *Shyness: Development, Consolidation and Change* (pp. 207-226). New York: Routledge.

Van Ameringen, M., Mancini, C., **Farvolden, P.**, & Oakman, J.M. (2000). Selective serotonin reuptake inhibitors in the treatment of social phobia: First-line treatment at the turn of the century. In (Ed.), K.J. Palmer, *Pharmacotherapy of Anxiety Disorders* (pp. 17-30). Auckland: ADIS International Ltd.

Bowers, K.S. & **Farvolden, P.** (1999). Revisiting a century-old Freudian slip-- from suggestion disavowed to the Truth repressed. In (Eds.), R.J. Sternberg & R.K. Wagner, *Readings in Cognitive Psychology*. Fort Worth, TX: Harcourt Brace College Publishers.

Bowers, K.S., **Farvolden, P.**, & Mermigis, L. (1994). Intuitive antecedents of insight. In (Eds.), S.M. Smith, T.M. Ward, & R.A. Finke, *The Creative Cognitive Approach*. Cambridge, MA: MIT

SELECTED PRESENTATIONS

Selected Scholarly Presentations

Landy, M. S. H., **Farvolden, P.**, Fitzpatrick, S., Wagner, A. C., Gentile, A. J., & Monson, C. M. (2020, November). Effectiveness of a Therapist-Assisted Online Cognitive Therapy for Posttraumatic Stress Symptoms. In Wells, S. Y. (Chair), *Meeting clients where they are: The use of technology to increase the reach of evidence-based PTSD treatments*. [Symposium]. Association for Behavioral and Cognitive Therapies 54th Annual Convention, Philadelphia, PA, United States.

Farvolden, P. (2020, March). *Who's using Beacon guided digital therapy in Canada?* Mental Health Commission of Canada E-mental Health Conference: Caring in a Digital World. Toronto, ON, Canada.

Irving, J. A. & **Farvolden, P.** (2019, May). Using therapist guided internet-based CBT to treat concurrent disorders. 7th Annual Addictions and Mental Health Ontario Conference. Toronto, ON, Canada.

Farvolden, P. (2018, October). Using digital technology (TAiCBT) to increase patient access to structured psychotherapy in a stepped care model. Health Quality Transformation Conference, Health Quality Ontario, Toronto, ON, Canada.

Farvolden, P. (2018, May). *Innovations in the treatment of anxiety: Ideas for improving access, cost-effectiveness, and outcome of CBT*. Canadian Association of Cognitive Behaviour Therapy Annual Conference. Vancouver, BC, Canada.

Farvolden, P. (2018, April). *Increasing patient access to structured psychotherapy through technology*. The Future of Psychotherapy Conference, University of Toronto Department of Psychiatry, Toronto, On, Canada.

Farvolden, P. (2017, May). *The world of private practice*. Canadian Association of Cognitive Behavioural Therapy Annual Conference, Ottawa, ON, Canada.

Lazar, N., Denisoff, E., & **Farvolden, P.** (2014, June). *Cognitive behavioural therapy for worry and generalized anxiety disorder*. Canadian Psychological Association Annual Conference, Montreal, QC, Canada.

van Mierlo, T., Hart, K., Fournier, R., Gee, B.A., Fracalanza, K., Vorstenbosch, V., **Farvolden, P.**, & Antony, M.M.. (2011, April). *Online CBT and job performance: An observational study*. International Society for Research on Internet Interventions (ISRII), Sydney, Australia.

Farvolden, P. (2010, September). *Managing Anxiety Disorders in a Workplace Setting*. Paper presented at the 60th Annual Meeting of the Canadian Psychiatric Association, Toronto, Ontario, Canada.

Gee, B.A., Fracalanza, K., Vorstenbosch, V., **Farvolden, P.**, Antony, M.M., & van Mierlo, T. (2010, November). *Capturing the characteristics of web-based cognitive behavioral therapy for depression users*. Paper presented at the meeting of the Association for Behavioral and Cognitive Therapies, San Francisco, CA.

Hood, H., Vorstenbosch, V., **Farvolden, P.**, Antony, M.M., & van Mierlo, T. (2010, November). *Look who's talking: Examining online support group use for a web-based CBT program for depression*. Paper presented at the meeting of the Association for Behavioral and Cognitive Therapies, San Francisco, CA.

Vorstenbosch, V., Hood, H., **Farvolden, P.**, Antony, M.M., & van Mierlo, T. (2010, June). *The utility of an online support group for treatment adherence to a web-based CBT for panic disorder*. Paper presented at the World Congress of Behavioral and Cognitive Therapies, Boston, MA.

Gee, B., Fracalanza, K. A., Vorstenbosch, V., **Farvolden, P.**, Antony, M. M., & van Mierlo, T. (2009, November). *Web-based cognitive behavioral therapy for depression: Patterns of use and effectiveness*. Paper presented at the meeting of the Association for Behavioral and Cognitive Therapies, New York, NY.

Hood, H., Vorstenbosch, V., John, B., Kloke, S., **Farvolden, P.**, Antony, M. M., & van Mierlo, T. (2009, November). *Tell me about it! Content analysis of support group discussion on a web-based panic disorder treatment program*. Paper presented at the meeting of the Association for Behavioral and Cognitive Therapies, New York, NY.

Rogojanski, J., Henderson, L., Farvolden, P., Koerner, N., Antony, M.M., & van Mierlo, T. (2009, July). *Internet-based cognitive behavioural therapy for panic disorder*. Paper presented at the meeting of the British Association for Behavioural and Cognitive Therapies, Exeter, UK.

Farvolden, P. (2007, August). *Promoting access to, engagement with, and efficacy of the treatment of mental health and addictions with eHealth programs and online social networks*. Eighth Annual International Conference of Human Services Information Technology Applications (HUSITA), Toronto, Canada.

Van Dyk, C., McCabe, S.B., **Farvolden, P.**, & Aquino, J. (2006, October). *Features of positive and negative affect and mood implicated in the recovery and resiliency of depression*. Annual meeting of the Society for Research in Psychopathology, San Diego, CA.

Van Mierlo, T., Cunningham, J., Fournier, R., **Farvolden, P.**, & Selby, P. (2006, May). *Determining the validity of self-reported dependence and treatment data collected via the World Wide Web: Legality, legitimacy and limitations*. Annual Epidemiology Symposium of the Kettil Bruun Society, Maastricht, Netherlands.

Farvolden, P. (2005, May). *Internet-Based treatment for panic disorder*. Anxiety Disorders Association of Canada, Second Biannual Conference, Toronto, Ontario, Canada.

Selby, P., **Farvolden, P.**, VanMierlo, T. & Fournier, R. (2005, November). *Moderated internet support groups: High reach, accessible and cost effective*. Presentation at the 2005 Conference on Tobacco or Health, Chicago, U.S.A.

Selby, P., **Farvolden, P.**, VanMierlo, T. & Fournier, R. (2005, October). *Co-Morbidity of mood and anxiety disorders among 750 registrants of an online smoking cessation program*. Presentation at the 2005 Critical Issues in eHealth Research Conference, Bethesda, Maryland, U.S.A.

Daskalakis Z.J., Fountain S.I., Christensen B.K., **Farvolden P.**, Fitzgerald P.B., Bagby M., Chen R. (2004, June). *The Relationship Between Cortical Inhibition, Impulsivity and Neuroticism: A Transcranial Magnetic Stimulation Study*. Society for Biological Psychiatry, New York, NY, 2004.

Farvolden, P. & Bagby, R.M. (2004, February). *Behavioural Activation and Inhibition Systems, the Five Factor Model and Their Association with Depression Severity and Response to Treatment*. International Society for Affective Disorders, Second Biennial International Conference, Cancun, Mexico.

Selby, P. & **Farvolden, P.** (2004, September). *Challenges in Collecting Data for Web-Based Smoking Cessation Research*. Web Assisted Tobacco Interventions (WATI) Conference, Toronto, ON, Canada.

Farvolden, P. & Selby, P. (2003, November). *Continuous Abstinence, Slips, and Relapse, for 1238 Users of Web-based Smoking Cessation Program*. Poster presented at the Association for the Advancement of Behavior Therapy, 37th Annual Conference, Boston, MA, U.S.A.

Farvolden, P. (2003, March). *Web-Based Collaborative Disease Management and Health Behaviour Change*. Paper presented at the Web-Based Interventions in Health Care Workshop, Centre for Health Informatics and Multiprofessional Education, Royal Free and University College Medical School, London, U.K.

Selby, P. & **Farvolden, P.** (2003, June). *Web-based Smoking Cessation: Reach and Quit Rates*. Presentation at the Society for Research on Nicotine and Tobacco, 9th Annual Conference, Helsinki, Finland.

Herve, H., Bagby, R.M., **Farvolden, P.**, & Toneatto, T. (2003, May). *Personality disorders and gambling in community ascertained male and female problem and social gamblers*. Paper presented at the 12th International Conference on Gambling and Risk-Taking. Vancouver, BC, Canada.

Farvolden, P. (2003, May). *Web-Based Collaborative Management for Anxiety Disorders*. Presentation at the First Canadian Anxiety Disorders Conference, Toronto, ON, Canada.

Farvolden, P., Rector, N., & Denisoff, E. (2003, March). *Personality, Attachment Style and Cognitive Predictors of Panic Symptom Activation: A Symptom Provocation Study*. Poster presented at the Anxiety Disorders Association of America, 23rd National Conference, Toronto, ON, Canada.

Selby, P. & **Farvolden, P.** (2003, November). *Web-Based smoking cessation. Quit rates of 4655 smokers*. Poster presented at the Society for Research on Nicotine and Tobacco, 9th Annual Conference, New Orleans, LA, U.S.A.

Van Ameringen, M., Mancini, C., Pipe, B., & **Farvolden, P.** (2002, November). *The addition of topiramate treatment for SSRI induced weight gain in anxiety disorder patients*. Poster presented at the Anxiety Disorders Association of America, 22nd National Conference, Austin, TX, U.S.A.

Selby, P., **Farvolden, P.**, & Van Mierlo, T. (2002, November). *Demographic characteristics, cessation history, and stages of change status among users of a Web-Based smoking cessation treatment program*. Poster presented at the National Conference on Tobacco or Health, San Francisco, CA, U.S.A.

Farvolden, P., Rector, N.A., Denisoff, E., & Zuroff, D.C. (2002, November). *Attachment style and anxiety sensitivity as predictors of symptom severity in the anxiety disorders spectrum*. Poster presented at the Association for the Advancement of Behavior Therapy, 36th Annual Conference, Reno, NV, U.S.A.

Van Ameringen, M., Mancini, C., **Farvolden, P.**, & Oakman, J. (2001, March). *A survey of the treatment of social phobia*. Poster presented at the Anxiety Disorders Association of America, 21st National Conference, Atlanta, GA, U.S.A.

Van Ameringen, M., Mancini, C., Oakman, J., **Farvolden, P.**, Walker, J.R., & Lane, R.M. (2001, March). *Sertraline in Generalized Social Phobia: Predictors of response*. Anxiety Disorders Association of America, 21st National Conference, Atlanta, GA, U.S.A.

Van Ameringen, M., Mancini, C., **Farvolden, P.**, & Oakman, J. (2001, May). *Social phobia treatment survey*. Paper presented at the 154th Annual Meeting of the American Psychiatric Association, New Orleans, LA, U.S.A.

Van Ameringen, M., Mancini, C., Oakman, J., **Farvolden, P.**, Walker, J.R., & Lane, R.M. (2001, may). *Predictors of sertraline response in Generalized Social Phobia*. Poster presented at the 154th Annual Meeting of the American Psychiatric Association, New Orleans, LA, U.S.A.

Van Ameringen, M., Mancini, C., Pipe, B., & **Farvolden, P.** (2001, May). *Topiramate for weight control in SSRI treated anxiety disorder patients*. Poster presented at the 154th Annual Meeting of the American Psychiatric Association, New Orleans, LA, U.S.A.

Van Ameringen, M., Mancini, C., Pipe, B., & **Farvolden, P.** (2001, June). *The addition of topiramate treatment for SSRI induced weight gain in anxiety disorder patients.* Poster presented at the 51st Annual Meeting of the Canadian Psychiatric Association, Montreal, QB, Canada.

Van Ameringen, M., Oakman, J.M., **Farvolden, P.**, Mancini, C., & Lane, R. (2001, May). *Sertraline response in Generalized Social Phobia: Predictors of response.* Poster presented at the 41st NCDEU Meeting, Boca Raton, FL, U.S.A.

Van Ameringen, M., Mancini, C., **Farvolden, P.**, & Oakman, J. (2001, October). *Pharmacological treatment options for social phobia.* Paper presented at the World Congress of Biological Psychiatry (WCBP), Berlin, Germany.

Van Ameringen, M., Mancini, C., Oakman, J., **Farvolden, P.**, Walker, J.R., & Lane, R.M. (2001, October). *Response to sertraline in Generalized Social Phobia.* Poster presented at the World Congress of Biological Psychiatry (WCBP), Berlin, Germany.

Van Ameringen, M., Mancini, C., & **Farvolden, P.** (2000, March). A survey of the use of alternative therapies among patients with anxiety disorders. Anxiety Disorders Association of America, 20th National Conference, Washington, DC, U.S.A.

Mancini, C., Van Ameringen, M., **Farvolden, P.**, & Davies, S. (2000, March). *A pilot study of group cognitive-behavioural therapy for adolescent with obsessive-compulsive disorder.* Poster presented at the Anxiety Disorders Association of America, 20th National Conference, Washington, DC, U.S.A.

Munn, C., Van Ameringen, M., **Farvolden, P.**, & Tougas, G. (2000). Psychiatric disorders in Irritable Bowel Syndrome: A pilot study. Poster presented at the 153rd Annual Meeting of the American Psychiatric Association, Chicago, IL, U.S.A.

Van Ameringen, M., Mancini, C., Oakman, J.M., **Farvolden, P.**, Taylor, C., & Scott, R. (2000, November). *Cognitive-behavioral group treatment for social phobia: A preliminary study of the effects of adding 12 more weeks of treatment.* Poster presented at the Anxiety Disorders Association of America, 20th National Conference, Washington, DC, U.S.A.

Van Ameringen, M., Mancini, C., & **Farvolden, P.** (2000). Use of alternative therapies among patients with anxiety disorders. Paper presented at the 153rd Annual Meeting of the American Psychiatric Association Meeting, Chicago, IL, U.S.A.

Mancini, C., Van Ameringen, M., & **Farvolden, P.** (2000, May). *Treatment resistant depression in patients with OCD.* Paper presented at the 153rd Annual Meeting of the American Psychiatric Association Meeting, Chicago, IL, U.S.A.

Mancini, C., Van Ameringen, M., & **Farvolden, P.** (2000, June). *Managing treatment-resistant depression in patients with primary obsessive compulsive disorder.* Paper presented at the 50th Annual Meeting of the Canadian Psychiatric Association, Victoria, BC, Canada.

Van Ameringen, M., Oakman, J.M., **Farvolden, P.**, Mancini, C., & Lane, R. (2000, April).

Predictors of sertraline response in social phobia. Poster presented at ACNP Meeting, San Juan, Puerto Rico.

Oakman, J.M., Van Ameringen, M., Mancini, C., **Farvolden, P.**, & Gifford, S. (1999, November). *Parenting style and the development of social phobia.* 19th National Conference of the Anxiety Disorders Association of America, San Diego, CA, U.S.A.

Van Ameringen, M., Mancini, C., Oakman, J., **Farvolden, P.**, & Holtzman, S. (1999, June). *A review of patients use of alternative therapies in anxiety disorders.* 49th Annual Meeting of the Canadian Psychiatric Association, Toronto, ON, Canada.

Mancini, C., Van Ameringen, M., Oakman, J., **Farvolden, P.**, & Thomson, E.K. (1999, June). *Towards a theoretical understanding of patients with obsessive compulsive disorder (OCD) and comorbid depression.* 49th Annual Meeting of the Canadian Psychiatric Association, Toronto, ON, Canada.

Oakman, J.M., Van Ameringen, M., Mancini, C., **Farvolden, P.**, & Gifford, S. (1999). Evaluating a latent class model of social anxiety. Poster presented at the 60th Annual Convention of the Canadian Psychological Association, Halifax, NS, Canada.

Mancini, C., Van Ameringen, M., Oakman, J., & **Farvolden, P.** (1999, November). *Serotonergic agents in the treatment of social phobia in children and adolescents: A case series.* Anxiety Disorders Association of America 19th National Conference, San Diego, CA, U.S.A.

Van Ameringen, M., Mancini, C., Oakman, J., & **Farvolden, P.** (1999, May). *A case series report of serotonergic agents in the treatment of social phobia in children and adolescents.* 152nd Annual Meeting of the American Psychiatric Association, Washington, DC, U.S.A.

Farvolden, P. (1998, March). *Finding what is true in what is false: Clinical judgment, scientific inquiry, and the recovered memory debate.* Paper presented at the 51st Annual Meeting of the Ontario Psychological Association, Toronto, ON, Canada.

Oakman, J.M., Van Ameringen, M., Mancini, C. & **Farvolden, P.** (1998, October). *Toward an improved nosology of social phobia: Dimensional or latent class?* Paper presented at the Internet World Congress '98, Hamilton, ON, Canada.

Farvolden, P., Bowers, K.S., & Woody, E.Z. (1995, October). *Hypnosis, absorption, and attention: Adventures in reaction time.* Paper presented at the 46th Annual Meeting of the Society for Clinical and Experimental Hypnosis, San Antonio, TX, U.S.A.

Farvolden, P., Bowers, K.S., & Woody, E.Z. (1994, October). *Suggested amnesia and the frontal lobes.* Paper presented at the 45th Annual Meeting of the Society for Clinical and Experimental Hypnosis, San Francisco, CA, U.S.A.

Farvolden, P., Bowers, K.S., & Woody, E.Z. (1993, October). *Hypnotic amnesia: Avoiding the intentional loop*. Paper presented at the 44th Annual Meeting of the Society for Clinical and Experimental Hypnosis, Chicago, IL, U.S.A.

Selected Community Presentations

Farvolden, P. (2022, June). *Addressing the rise of psychological injury claims – Implications for Workers' Compensation*. Association of Workers Compensation Boards of Canada 2022 Virtual Governance Summit.

Farvolden, P. & Worndl, K. (2019., October). Mental health questions you always wanted to ask. Lumino Health Webinar. Toronto, ON, Canada.

Duboc, C. & **Farvolden, P.** (2019, May). *Applying evidence from psychological therapy programs across the globe to your employee mental health initiative*. Health Benefits and Pension Summit. Benefits Canada. Toronto, ON, Canada.

Farvolden, P. (2019, April). *Working well*. Medavie Blue Cross Benefits3 Annual Conference. Halifax, NS, Canada.

Farvolden, P. & Slade, K. (2018, April). *Chronic mental stress: Bridging the care gap for workers*. AdvantAge Ontario Annual General Meeting. Toronto, Ontario, Canada.

Farvolden, P. & Gove, P. (2017, November). *And now for something completely different episode 2: Treating mental illness in Canada*. Greenshield Canada. Toronto, On, Canada.

Farvolden, P. (2007, November). *Understanding accommodation and return to work for mental health and addiction problems*. Presentation to the Legal Directors and Senior Management Group at the Ministry of the Attorney General, Toronto, ON, Canada.

Farvolden, P. (2007, September). *Making return to work work for mental health claims*. Presentation for WSIB Schedule 2 Employers Group 18th Annual Workplace Health & Safety and Disability Management Conference and Trade Show, Toronto, ON, Canada.

Farvolden, P. (2007, May). *Work life balance*. Presentation to the Justice Technology Services Conference, Ministry of Community Safety and Correctional Services, The Nottawasaga Inn, ON, Canada.

Farvolden, P. (2007, May). *Challenges in return to work for mental health claims*. Presentation for the Canadian Life and Health Insurance Association Annual Conference, Niagara Falls, ON, Canada.

Farvolden, P. (2006, December). *Mental health and stress at work and at home*. Presentation for the Centre for Forensic Sciences, Toronto< ON, Canada.

Farvolden, P. (2006, November). *Best practices for managing traumatic psychological injury in a workers compensation setting*. Presentation to WSIB Nurse Case Managers and Case Adjudicators, WSIB, Toronto, ON, Canada.

Farvolden, P. (2006, November). *Managing workplace stress*. Presentation for the Canadian Security and Intelligence Service, Toronto, ON, Canada.

Farvolden, P. (2005, October). *Cognitive behavioural therapy of PTSD following a workplace accident*. Department of Psychiatry, Peterborough Regional Health Centre, Peterborough, ON, Canada.

Farvolden, P. (2005, June). *Making sense of research findings: The soap opera of science*. Presentation at the Institute of Addiction and Mental Health Studies for Journalists, Centre for Addiction and Mental Health, Toronto, ON,, Canada.

Farvolden, P. (2005, April). *Cognitive behavioural therapy of PTSD*. Presentation to WSIB Nurse Case Managers and Case Adjudicators, WSIB, Toronto, ON, Canada.

Farvolden, P. (2005, February). *Understanding trauma and its links to substance use and mentalhealth problems*. Presentation at the Community Information Forum on Addiction and Mental Health, part of a series of forums provided by The Centre of Addiction and Mental Health and the Mood Disorders Association of Ontario, Toronto, ON, Canada.

Farvolden, P. (2004, June). *Anxiety and comorbid depression: Current research*. Presentation at the Mood Disorders Association of Ontario Conference. Kempenfelt Bay, Barrie, ON, Canada.

Farvolden, P. (2004, May). *Anxiety and comorbid depression: Current research*. Presentation at the Community Information Forum on Addiction and Mental Health, part of a series of forums provided by The Centre of Addiction and Mental Health and The Mood Disorders Association of Ontario, Toronto, ON, Canada.